BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+9.82%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.17B
AUM Growth
+$6.17B
(+0.29%)
Cap. Flow
-$269M
Cap. Flow
% of AUM
-4.35%
Top 10 Holdings %
Top 10 Hldgs %
39.22%
Holding
177
New
11
Increased
57
Reduced
71
Closed
15
Top Buys
| 1 |
Evolent Health
EVH
|
$28.3M |
| 2 |
Exact Sciences
EXAS
|
$19.8M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$19.6M |
| 4 |
Abbott
ABT
|
$15.7M |
| 5 |
Inspire Medical Systems
INSP
|
$14.8M |
Top Sells
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$36.5M |
| 2 |
Insmed
INSM
|
$36.2M |
| 3 |
argenx
ARGX
|
$32M |
| 4 |
Charles River Laboratories
CRL
|
$31.4M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$30.5M |
Sector Composition
| 1 | Healthcare | 99.93% |
| 2 | Industrials | 0.04% |
| 3 | Communication Services | 0.02% |
| 4 | Technology | 0.01% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Protagonist Therapeutics
PTGX
$3.62B
| $556K | 0.01% |
12,346
-2,800
| -18% | -$126K |
|
127
Apellis Pharmaceuticals
APLS
$3.51B
| $549K | 0.01% |
19,046
-425,358
| -96% | -$12.3M |
|
128
ADMA Biologics
ADMA
$4.03B
| $518K | 0.01% |
25,900
-5,000
| -16% | -$100K |
|
129
Biogen
BIIB
$20.8B
| $511K | 0.01% |
2,634
-3,268
| -55% | -$633K |
|
130
HUTCHMED
HCM
$2.62B
| $469K | 0.01% |
24,015
-1,125,142
| -98% | -$22M |
|
131
Denali Therapeutics
DNLI
$2.24B
| $457K | 0.01% |
+15,700
| New | +$457K |
|
132
Viatris
VTRS
$12.3B
| $456K | 0.01% |
39,283
+12,752
| +48% | +$148K |
|
133
Travere Therapeutics
TVTX
$1.75B
| $434K | 0.01% |
+31,000
| New | +$434K |
|
134
Merus
MRUS
$5.04B
| $400K | 0.01% |
8,000
-1,800
| -18% | -$89.9K |
|
135
Arcutis Biotherapeutics
ARQT
$1.91B
| $367K | 0.01% |
39,500
+22,000
| +126% | +$205K |
|
136
Arcellx
ACLX
$3.95B
| $334K | 0.01% |
+4,000
| New | +$334K |
|
137
Xenon Pharmaceuticals
XENE
$2.99B
| $323K | 0.01% |
8,200
-2,000
| -20% | -$78.7K |
|
138
Nike
NKE
$110B
| $309K | 0.01% |
3,500
| – | – |
|
|
BPMC
139
DELISTED
Blueprint Medicines
BPMC
| $296K | ﹤0.01% |
3,200
-1,900
| -37% | -$176K |
|
140
Kura Oncology
KURA
$732M
| $266K | ﹤0.01% |
13,600
+3,600
| +36% | +$70.3K |
|
141
BridgeBio Pharma
BBIO
$9.91B
| $265K | ﹤0.01% |
10,400
-2,400
| -19% | -$61.1K |
|
142
Madrigal Pharmaceuticals
MDGL
$9.7B
| $233K | ﹤0.01% |
1,100
| – | – |
|
143
IDEAYA Biosciences
IDYA
$2.26B
| $228K | ﹤0.01% |
7,200
+1,500
| +26% | +$47.5K |
|
144
Ultragenyx Pharmaceutical
RARE
$3.04B
| $222K | ﹤0.01% |
4,000
| – | – |
|
145
MoonLake Immunotherapeutics
MLTX
$3.78B
| $222K | ﹤0.01% |
4,400
| – | – |
|
146
Baidu
BIDU
$33.1B
| $211K | ﹤0.01% |
2,000
| – | – |
|
147
Mineralys Therapeutics
MLYS
$1.94B
| $200K | ﹤0.01% |
16,499
-1,000
| -6% | -$12.1K |
|
148
Garmin
GRMN
$45.6B
| $185K | ﹤0.01% |
1,050
| – | – |
|
149
Nurix Therapeutics
NRIX
$723M
| $180K | ﹤0.01% |
+8,000
| New | +$180K |
|
150
Rocket Pharmaceuticals
RCKT
$358M
| $172K | ﹤0.01% |
9,300
-10,400
| -53% | -$192K |
|